I am deeply indebted to a large number of scientists, medical researchers, and others to whom I can only say thank you. The following are acknowledged for specific participation:

William W. Halcomb, now of Mesa, Arizona, conducted our 1984 clinical trial. Donald R. Davis and Mitchell E. Gidseg of Austin, Texas, helped in statistical analyses, writing the original 1984 text, and in many fruitful discussions.

Bruce D. Korant, of Du Pont Central Research in Wilmington, Delaware, worked with Zn²⁺ ions and rhinoviruses and provided helpful insight.

Rinaldo Pellegrini of Milan, Italy, Medical-Scientific Director of RBS Pharma-Milan, took the time to visit with us and listen to our warnings about metallic chelators and made the flavor-masked zinc gluconate lozenges successfully demonstrated by the British Medical Research Council Common Cold Unit in Salisbury, England (MRC).

David A. J. Tyrrell and co-workers at the MRC Common Cold Unit had the courage to publish the clinical truth, even though they could not determine the operative mechanism, and for his kind foreword remarks.

Guy Berthon, Director of Research at INSERM Unit 305 in Toulouse, France, went far out of his way to help, and single-handedly saved this line of research.

Charles A. Pasternak, at St. George's Hospital Medical School, University of London, took the time to visit with me and explain how Zn²⁺ ions could stabilize cell plasma membranes and perhaps be the means by which zinc lozenges shorten colds. I am also grateful for his kind foreword.

Bill Bannen of General Nutrition Products in Greenville, South Carolina, disclosed the McNeil formulation.

Claude. B. Goswick of Texas A&M University, College Station, Texas, revealed the actual dosages used in the McNeil clinical trial.

Jack M. Gwaltney Jr., of the University of Virginia at Charlottesville, Virginia, provided frank and helpful comments.

R. Bruce Martin, University of Virginia at Charlottesville, Virginia, provided the formula and zinc-citric acid speciation data applicable to the Bristol Myers lozenges.

R. J. E. Williams of Faulding LTD, Adelaide, South Australia, disclosed the formulation of the effervescent lozenges used by Robert M. Douglas. Robert M. Douglas, now at the Australian National University, National Centre for Epidemiology and Population Health in Canberra, has shown continued interest.

M. L. McCutcheon of the University of Minnesota at Duluth, sent me an unpublished account of their failed zinc aspartate study (0 ZIA), which helped show that nothing happens if there are no zinc ions. Ira Hill of Research Directions in Locust, New Jersey, lent support and technical assistance.

James W. McGinity, Salomon A. Stavchancsky, Roland A. Bodmeier, and others at the Drug Dynamics Institute, College of Pharmacy, University of Texas in Austin, gave much and varied assistance.

Paul T. Zeltzer, now at the Developmental Biology Group at UCLA in Los Angeles started me on this line of inquiry while he was my daughter's oncologist. Richard M. Holt of Children's Hospital of Austin, Texas provided pediatric services and particpated in many helpful conversations. Michael Castleman, author, of San Francisco, popularized zinc lozenges for colds and has given me endless support.

Allison E. Rowland of Texas A&M University, College Station, Texas, contributed much-needed editorial services.

Most of all, I very much appreciate the support provided to me by my family. Thelma Lloyd Eby, my mother (deceased), who financed the beginning of this research; Patsy Ann Eby, my beloved wife who gives and gives and gives without end; Karen Lynn Eby, my beloved daughter, and the child who prompted the insight as well as the need for this line of inquiry at the tender age of three; and Colin Martin Eby, my beloved son, for his support and understanding.

George A. Eby